The trademark Cymerus refers to the patented process of generating cell-based products from intermediate cells
At present, Cynata is focused on the production of mesenchymal stem cell (MSC)-based products using the Cymerus technology.
An example of an MSC product is CYP-001, targeting graft-versus-host-disease (GvHD) for which a Phase I clinical trial has been completed.
During 2019, Fujifilm did a licensing deal with Cynata for CYP-001 and GvHD for a US$3 million upfront payment and future payments of up to US$43 million.
Aims to commercialise technology via further licence agreements
Cynata continues to focus on early commercialisation of Cynata’s Cymerus MSC products and is in active commercial discussions for numerous therapeutic targets.
During calendar year 2020, Cynata plans to be progressing to three Phase II trials in for GvHD (funded by Fujifilm), CLI, and osteoarthritis.
The company also continues to investigate the therapeutic potential in numerous additional target areas.
It is worth noting the Cymerus process has a number of key advantages including being only platform in the world able to produce commercial quantities of MSCs from a single source.
Five companies presenting
Register now for the CEO Sessions